Details of Disease

General Information of Disease (ID: DISAX6J3)

• Disease Name: Hot flushes
• Disease Class: GA30: Menopausal disorder
• Disease Hierarchy:
  DIS01GPL: Grass pollen hypersensitivity
  DISAX6J3: Hot flushes
• ICD Code:
  ICD-11: ICD-11: GA30
  ICD-10: ICD-10: N95.1

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 14 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Bazedoxifene	DMY85QW	Approved	Small molecular drug	[1]
Conjugated Estrogens	DMLT0E1	Approved	Small molecular drug	[2]
Drospirenone	DM1A9W3	Approved	Small molecular drug	[3]
Estradiol	DMUNTE3	Approved	Small molecular drug	[4]
Ethinyl Estradiol	DMODJ40	Approved	Small molecular drug	[5]
Fezolinetant	DMHDQZD	Approved	Small molecule	[6]
Levonorgestrel	DM1DP7T	Approved	Small molecular drug	[7]
Methyltestosterone	DMWLFGO	Approved	Small molecular drug	[8]
Norethindrone	DMTY169	Approved	Small molecular drug	[9]
Norgestimate	DMYP4XC	Approved	Small molecular drug	[10]
Paroxetine	DM5PVQE	Approved	Small molecular drug	[11]
Progesterone	DMUY35B	Approved	Small molecular drug	[12]
Quinestrol	DMJ6H1Z	Approved	Small molecular drug	[13]
Testosterone	DM7HUNW	Approved	Small molecular drug	[14]

This Disease is Treated as An Indication in 2 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Elinzanetant	DMC6EFI	Phase 3	Small molecule	[15]
AUS-131	DMUXO3Z	Phase 2	NA	[16]

This Disease is Treated as An Indication in 1 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
ITI-014	DM0S9D2	Investigative	NA	[17]

Molecular Interaction Atlas (MIA) of This Disease

References

• [1] Bazedoxifene FDA Label
• [2] Raloxifene. Drugs Aging. 1998 Apr;12(4):335-41; discussion 342.
• [3] Drospirenone FDA Label
• [4] Estradiol FDA Label
• [5] Ethinyl estradiol FDA Label
• [6] FDA Approved Drug Products from FDA Official Website.
• [7] Levonorgestrel FDA Label
• [8] Methyltestosterone FDA Label
• [9] Norethindrone FDA Label
• [10] Norgestimate FDA Label
• [11] Paroxetine FDA Label
• [12] Progesterone FDA Label
• [13] Quinestrol FDA Label
• [14] Testosterone FDA Label
• [15] ClinicalTrials.gov (NCT05099159) A Double-blind, Randomized, Placebo-controlled Multicenter Study to Investigate Efficacy and Safety of Elinzanetant for the Treatment of Vasomotor Symptoms Over 26 Weeks in Postmenopausal Women. U.S.National Institutes of Health.
• [16] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030256)
• [17] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.